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C
ystic ﬁbrosis–related diabetes
(CFRD) is the most common co-
morbidity in subjects with cystic ﬁ-
brosis (CF). A consensus conference on
CFRD was cosponsored by the Cystic Fi-
brosis Foundation (CFF), the American
Diabetes Association (ADA), and the Pe-
diatric Endocrine Society (PES) in Sep-
tember 2009. The committee’s evidence-
based recommendations for clinical
management of CFRD are published in
this issue of Diabetes Care. This review
articledescribestheepidemiology,patho-
genesis, and prognostic implications of
CFRD.
Epidemiology
CFRD is part of a continuum of glucose
tolerance abnormalities, ranging from
normal glucose tolerance (NGT), to im-
paired glucose tolerance (IGT), to CFRD
without fasting hyperglycemia (CFRD
FH), to CFRD with fasting hyperglyce-
mia (CFRD FH) (Fig. 1). Unlike pa-
tients with type 1 diabetes, those with
CFRD do not develop complete absence
of insulin secretion. At the other end of
the spectrum, few CF patients have truly
normal glucose metabolism. Approxi-
mately 20% of children who are catego-
rized as having NGT based on their
fasting and 2-h oral glucose tolerance test
(OGTT) glucose levels have glucose ele-
vation 200 mg/dl (11.1 mmol/l) mid-
OGTT, which is termed indeterminate
glycemia (INDET) (1). As in the general
population where INDET is a risk factor
for progression to diabetes (2), INDET in
children with CF is associated with early
development of CFRD (1). Home contin-
uous glucose monitoring (CGM) has
shown that intermittent, asymptomatic
hyperglycemia is common even in CF pa-
tients whose OGTT is normal, but the
prognostic signiﬁcance of these early im-
pairments in glucose metabolism is un-
known (3,4). Impaired fasting glucose
has also been described in CF (5,6).
CFRD is present in about 20% of ad-
olescents and 40–50% of adults with CF
(7) (Fig. 2). It is rare in childhood but has
been described in children of all ages in-
cluding infants (8–11). Beginning in the
teenageyears,theincidenceis3%,with
some but not all centers reporting an
overall female predominance (7,12). In
youngerindividualsCFRDFHpredom-
inates, but the prevalence of fasting hy-
perglycemia rises with age (7). Diabetes is
associated with more severe CF gene mu-
tations, increasing age, worse pulmonary
function, undernutrition, liver dysfunc-
tion, pancreatic insufﬁciency, and corti-
costeroid use (12–15).
Pathophysiology
CFRD shares features of both type 1 and
type 2 diabetes, but has enough patho-
physiological and clinical differences to
warrant separate diagnostic classiﬁcation
(Table 1). As in type 1 diabetes, individ-
uals with CFRD are not obese, it often
occurs in young people, insulin insufﬁ-
ciency is the primary defect, and meta-
bolic syndrome features (hyperlipidemia,
hypertension, visceral adiposity) are not
usually present. Clinical management is
similar to type 1 diabetes in the honey-
moon phase. As in type 2 diabetes, this is
not an autoimmune disease, insulin resis-
tance is present (albeit usually mild), and
ketosis is rare. Genetically, CFRD may be
related to type 2 diabetes, as described
below.
Insulin insufﬁciency. Reduced -cell
mass leading to insulin insufﬁciency is
the hallmark of CFRD. The CF gene de-
fect leads to abnormal or absent CF
transmembrane conductance regulator
(CFTR), a chloride channel that also in-
ﬂuences sodium and water transport.
Thick, viscous secretions cause inﬂam-
mation, obstruction, and destruction of
small ducts in the lungs, pancreas, liver,
and reproductive organs. Autopsy ﬁnd-
ings include ﬁbrosis and atrophy of the
pancreas with 50% reduction of the to-
tal islet mass (16–18).
Multiple studies have shown im-
paired ﬁrst–phase insulin secretion in re-
sponse to glucose, arginine, or glucagon,
even in subjects with NGT (19–24). In
response to oral glucose, the earliest de-
fect is delayed insulin secretion, followed
over time by a progressively diminished
totalinsulinresponse(22–32).The-cell
destruction is not complete and residual
endogenous insulin secretion is present,
so these patients are not prone to ketosis.
The lack of ketosis may also be related to
low glucagon levels. While fasting gluca-
gon levels are normal, CF patients are not
able to appropriately increase glucagon
secretion in response to arginine or hypo-
glycemia (21,24), consistent with re-
duced -cell mass. Incretin levels (gastric
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tide 1) are normal in CF (23), which may
help to explain why glucose excursion is
better in response to a mixed meal com-
pared with oral glucose (33).
Insulin resistance. Euglycemic clamp
studies generally demonstrate normal pe-
ripheralmuscleinsulinsensitivityinnon-
diabetic CF patients (34–37), although
insulin resistance has also been described
and may be related to greater severity of
illness and inﬂammation (38,39). Modest
peripheral insulin resistance occurs once
diabetes develops (35–38).
The most surprising clamp ﬁnding is
that liver insulin resistance with elevated
hepatic glucose production (both in the
fasting state and in response to insulin in-
fusion) occurs not only in CF patients
with diabetes, but also in those with com-
pletely normal fasting glucose levels
(37,40,41). It has been hypothesized that
the increased energy needs of CF patients
create a physiologic balance between ele-
vated hepatic glucose production and
high glucose demand.
Genetic predisposition to diabetes. It
is still not clear whether the underlying
CF gene defect predisposes patients to di-
abetes. There has been speculation that
-cell failure is related to endoplasmic re-
ticulum stress from retained abnormal
CFTR protein, leading to apoptosis (42).
It has not deﬁnitively been shown, how-
ever, that CFTR is even expressed in
-cells. In a mouse model of CF, CFTR

mice had greater impairment of insulin
secretionthancontrolmiceafterlow-dose
streptozotocin despite a similar loss of is-
lets, perhaps suggesting an intrinsic in-
volvement of CFTR in -cell function
(43).
What about genes predisposing to
type 1 or type 2 diabetes? With a few ex-
ceptions (44–46), type 1 diabetes auto-
antibodies have not been found in
patients with CFRD, and HLA DR3/4 as-
sociationshavebeensimilartothegeneral
population (22,25,27,28,47–50). It is,
however, possible for CF and autoim-
mune type 1 diabetes to occasionally co-
exist in the same individual (51,52).
There are interesting new data dem-
onstrating genetic associations between
type 2 diabetes and CFRD. The earliest
suggestion that CFRD might be related to
type 2 diabetes was a ﬁnding of islet amy-
loiddepositioninindividualswithCFRD,
similartotype2butnottype1diabetesor
chronicpancreatitis(16).Morerecently,a
family history of type 2 diabetes was
found to increase the risk of CFRD (53).
The concordance rate for diabetes was
substantiallyhigherinmonozygoustwins
comparedwithdizygoustwinsorsiblings
with CF (54). Variation in a type 2 diabe-
tes susceptibility gene, transcription fac-
tor 7-like 2 (TCF7L2), was shown to be
associated with diabetes in CF and de-
creased the mean age of diabetes diagno-
sisby7years(53).Anassociationwasalso
found between CFRD and a genetic poly-
morphism in calpain-10, which has been
reported in type 2 diabetes (55). Cal-
pain-10 is involved in insulin secretion
and inﬂammation, both of which may be
relevant in CFRD. Thus, although more
workneedstobedoneinthisarea,genetic
variantsconferringriskfortype2diabetes
in the general population appear to be
modiﬁers of diabetes risk in CF.
Integrated hypothesis of CFRD patho-
physiology. We hypothesize that all CF
patients with pancreatic exocrine insufﬁ-
ciency have pancreatic endocrine insufﬁ-
ciency related to physical scarring and
destruction of islets. Those patients who
arepancreaticsufﬁcientbecauseofmilder
defects in CFTR experience less islet de-
struction, although chronic pancreatitis
may damage and destroy islets over time.
Despitesigniﬁcantlyreduced-cellmass,
many people with CF have only mild glu-
cose tolerance abnormalities because
their peripheral insulin sensitivity is nor-
Figure 1—The spectrum of glucose tolerance in CF. Unlike patients with type 1 diabetes, insulin secretion is never completely absent in CFRD.
Clinicaldeterioration(pulmonaryfunction,underweight)isassociatedwithworseglucosetolerancestatus.AbnlCGMabnormalhomecontinuous
glucose monitoring, T1D  type 1 diabetes, INDET  indeterminate glycemia.
Figure 2—Prevalence of CFRD based on 2005–2008 data for all patients within each age-group
at the University of Minnesota. Data are presented for all patients with CFRD (CFRD total) and
separately by fasting hyperglycemia status (ref. 7).
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petent enough to compensate. More
severe glucose tolerance abnormalities
develop in those who either have worse
inﬂammation and thus greater insulin re-
sistance, or who have intrinsic -cell dys-
function related to type 2 diabetes–
associated genetic variations.
Prognostic implications of diabetes
in CF
Diabetes macrovascular and microvas-
cular complications. Patients with type
1 and type 2 diabetes die from macrovas-
cular disease. This is not the case in
CFRD. Although many CF patients now
live into their sixth and seventh decades,
there has never yet been a CF patient re-
ported to have died from atherosclerotic
cardiovascular disease. This may be re-
lated to the fact that cholesterol levels are
generally low despite a diet high in satu-
rated fat (56). While low cholesterol
levels have been attributed to fat malab-
sorption,theremayalsobesomeintrinsic
connection to the basic CF gene defect
since levels are low even in well-
nourished patients.
Microvascular complications do oc-
curinCFRDand,asinallindividualswith
diabetes, are related to the duration and
metabolic control of diabetes (57–60).
They typically do not become apparent
until the diabetes has progressed to fast-
ing hyperglycemia (57). Mild neuropathy
is the most prevalent microvascular com-
plication in CFRD (57). It is found in
about half of the patients who have had
diabetesformorethan10years,similarto
prevalence rates for other types of diabe-
tes. The most common ﬁndings are re-
duced sural sensory nerve action
potential amplitude and impaired cardio-
respiratory reﬂexes, consistent with
diabetic polyneuropathy. In contrast, ret-
inopathy and nephropathy appear to be
less frequent and less severe than in other
diabetes populations. In CF patients with
more than 10 years diabetes duration,
14%hadmicroalbuminuriaand16%had
retinopathy (57). The eyes and the kid-
neys may be somewhat protected in
CFRD because of the presence of residual
endogenous insulin secretion or because
metabolicriskfactorssuchassevereinsu-
lin resistance, hypertension, and hyper-
lipidemia are seldom present in this
population. Delayed gastric emptying is
found in about half of CFRD patients, but
it is also common in CF patients who do
not have diabetes; diabetes may exacer-
bate gastrointestinal motility problems
intrinsic to CF.
TheinﬂuenceofdiabetesonCFpulmo-
nary function. The most important
morbidity in subjects with CFRD may be
the impact of diabetes on pulmonary
function. Both insulin insufﬁciency and
hyperglycemia negatively affect CF lung
disease.Nutritionalstatusandpulmonary
function begin to decline in CF patients
severalyearsbeforetheactualdiagnosisof
CFRD in the pre-diabetic period when
minimal hyperglycemia is present
(50,61,62). The rate of pulmonary func-
tion decline is directly related to the se-
verity of insulin insufﬁciency; when
followed for 4 years after a baseline
OGTT, patients with IGT had a greater
loss of lung function than those with
NGT, and those with CFRD FH had the
greatest loss (63). The rate of pulmonary
function decline was inversely related to
the baseline OGTT area under the curve
for insulin.
CF lung function is critically depen-
dent on maintaining normal weight and
lean body mass. Insulin insufﬁciency
compromises nutritional status by creat-
ingacatabolicstatewithexcessiveprotein
and fat breakdown (64–68). There have
been multiple reports demonstrating that
insulin replacement therapy improves
nutritional status and pulmonary func-
tion in patients with CFRD (50,69–73).
Recently, a multicenter, randomized, pla-
cebo-controlled trial demonstrated that
insulin therapy was able to reverse
chronic weight loss in adult patients with
CFRD FH (74), ending the controversy
about whether insulin should be pre-
scribed for this “milder” form of diabetes.
Whether patients with less severe glucose
toleranceabnormalitiessuchasIGTorin-
determinate glycemia would beneﬁt from
insulin replacement remains to be deter-
mined, but small studies in adults and
children suggest that this might be the
case (72,75).
While it is often said that the nutri-
tional consequences of insulin insufﬁ-
ciency are of greater concern than the
metabolic effects of hyperglycemia in CF,
highbloodglucoselevelsmayalsoplayan
importantroleinpulmonaryfunctionde-
cline, even in patients with only intermit-
tent postprandial glucose elevation.
Table 1—CFRD compared with type 1 and type 2 diabetes
CFRD Type 1 diabetes Type 2 diabetes
Prevalence in population 35% 0.2%* 11%*
Peak age of onset 20–24 years Childhood, adolescence Mid to late adulthood
Usual body habitus Normal to underweight Normal Obese
Insulin deﬁciency Severe but not complete Complete Partial, variable
Insulin resistance Usually modest, waxes and wanes
with infection
Usually modest Severe
Autoimmune etiology No Yes No
Ketones Rare Yes Rare
A1C Unpredictable relation to mean
blood glucose
Related to mean blood glucose Related to mean blood glucose
Usual treatment Insulin Insulin Oral agents, insulin
Microvascular complications Yes Yes Yes
Macrovascular complications No Yes Yes
Metabolic syndrome features No No Yes
Cause of death Lung disease Cardiovascular Cardiovascular
*Source: National Diabetes Information Clearinghouse, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
(http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#allage).
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elevated (144 mg/dl, 8.0 mmol/l), air-
way glucose concentrations are also
elevated in CF patients, and this envi-
ronment has been shown to promote
growth of respiratory pathogens (76).
In addition, hyperglycemia has been
noted to be associated with increased
oxidative stress in CF (77). Thus, high
bloodglucoselevelsmaycontributetoCF
lung disease by creating a proinﬂamma-
tory, pro-bacteria environment in the
airways.Thepresenceoffastinghypergly-
cemia does not appear to be a critical de-
terminant since lung function and
nutritional status do not differ between
CFRD FH and CFRD FH (7).
Excessive mortality in CFRD. Unlike
patients with type 1 and type 2 diabetes,
patients with CFRD die from respiratory
failure due to chronic lung inﬂammation
andinfection.Theﬁrstinklingthatdiabe-
tes might impact survival from pulmo-
nary disease came in 1988 when it was
reportedthatlessthan25%ofCFpatients
with diabetes reached the age of 30 years
compared with about 60% of those with-
out diabetes (62). Since then, multiple
studieshaveshownthattheadditionaldi-
agnosis of diabetes in subjects with CF is
associated with worse nutritional status,
more severe lung disease, and greater
mortality (14,15,78). For reasons that
haveneverbeenwellunderstood,females
with CFRD have been noted to be partic-
ularly vulnerable (32,78,79).
On a positive note, longitudinal eval-
uation at one large CF center has demon-
strated steady improvements over time in
CFRD-associated mortality. Comparison
of the periods between 1992–1997 and
2003–2008 revealed that female mortal-
ity dropped by 50% from 6.9 to 3.2
deaths per 100 patient-years, and male
mortality dropped from 6.5 to 3.8 deaths
Figure3—CFRDmortalityper100patient-yearsbysexandagedecadeoverthreetimeperiods:2003–2008,1998–2002,and1992–1997.Females
areshowninred,andmalesareshowninblue.CFpatientswithdiabetesareshownwithsolidlines,andCFpatientswithoutdiabetesareshownwith
dashedlines.Thegapinmortalitybetweenthosewithandwithoutdiabeteshasdiminishedoverthesetimeperiods,andthesexdifferenceinmortality
has disappeared in the most current analysis (ref. 7) DM, diabetes.
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diabetes (7). Mortality is shown in Fig. 3
by diabetes status, sex, and age decade
over three time intervals from 1992–
2008. In 2008, lung function was still
worse in CF patients with diabetes com-
pared with those without diabetes, but
the gap had narrowed and there was no
longer a sex difference in mortality. This
improvement was attributed to early de-
tection of diabetes and aggressive man-
agement with insulin therapy.
Conclusions
Abnormal glucose tolerance, including
diabetes, is present in the majority of in-
dividualswithCFandisrelatedtoinsulin
insufﬁciency and, to a lesser extent, to in-
sulin resistance. While insulin insufﬁ-
ciency is directly related to reduced islet
mass, the functional capacity of the re-
maining -cells may be genetically deter-
mined. Insulin insufﬁciency creates a
catabolic state and a nutritional compro-
mise, which has a negative impact on
pulmonary function and survival. Hyper-
glycemia also contributes to lung disease
by promoting oxidative stress, inﬂamma-
tion, and infection. CFRD is associated
with diabetes microvascular complica-
tions and with excessively high rates of
death from CF lung disease, particularly
inwomen.However,earlydetectioncom-
bined with aggressive insulin therapy has
been shown to reduce the mortality gap
betweenCFpatientswithandwithoutdi-
abetes and to eliminate the sex disparity
in survival.
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